Results 151 to 160 of about 303,943 (292)

TAVR in Male Patients With Large Aortic Valve Annuli: A Propensity‐Matched Analysis of Balloon‐Expandable Versus Self‐Expanding Valves

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Trans‐catheter aortic valve replacement (TAVR) in patients with large annuli poses procedural difficulties and possible complications. Aims We sought to compare the peri‐procedural and long‐term outcomes of patients with large annuli undergoing TAVR with self‐expanding (SEV) versus balloon‐expandable (BEV) valves.
Lior Zornitzki, Itamar Loewenstein, Shir Frydman, Maayan Konigstein, Jeremy Ben‐Shoshan, Yaron Arbel, Israel Barbash, Ran Kornowski, Gabby G. Elbaz, Danny Dvir, Ariel Finkelstein, Shmuel Banai, Arie Steinvil   +12 more
wiley   +1 more source

Prevalence of anxiety and depression among end-stage kidney disease patients on dialysis: A cross-sectional multiple-centre study in Riyadh, Saudi Arabia

Journal of Family Medicine and Primary Care
Introduction Patients with end-stage kidney disease (ESKD) in need of renal replacement therapy are estimated to number between 4.902 and 7.083 million. Studies have shown that depression and anxiety are the most common mental illnesses among people with
Omar A. AlShammari, Sara O. AlFadil, Abdulaziz AlShabibi, Hussein Mohamed, Mohammd Alomi, Khalid Almatham   +5 more
doaj   +1 more source

Association Between D‐amino Acids in Natto (fermented soybeans) and Kidney Dysfunction

ChemFoodChem, EarlyView.
XX XX ABSTRACT In this study, we examined clinical and cohort data to explore the potential renoprotective effects of natto (fermented soybeans) consumption and its relationship with D‐amino acids. In a clinical study, ten healthy adults consumed one 40‐g pack of natto three times in a single day, and plasma and urine samples were collected 1 h and 24 ...
Yusuke Nakade, Tadashi Toyama, Akinori Hara, Shigefumi Okamoto, Hiroaki Masuoka, Wataru Suda, Masashi Mita, Yuna Miyajima, Keishi Mizuguchi, Takeo Yuno, Hiroka Yamazaki, Hiroki Ohtani, Hoang Thuy Linh, Megumi Oshima, Miho Shimizu, Norihiko Sakai, Hiromasa Tsujiguchi, Hiroyuki Nakamura, Yasunori Iwata, Takashi Wada   +19 more
wiley   +1 more source

Protective Effect of Probiotic Against Progression of Chronic Kidney Disease: A Randomized Clinical Study

Medical Journal of Babylon
Background:Chronic kidney disease (CKD) is a gradual, irreversible disease with severe global health implications. By raising the level of urea toxins in the body, gut microbiota dysbiosis may hasten the onset of chronic renal disease.
Waleed Khaild Rahman, Ihsan Salah Rabea, Mudhfar Mohammed Meizel   +2 more
doaj   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function

Clinical Pharmacology &Therapeutics, EarlyView.
The FDA published guidance on assessing pharmacokinetics (PK) in participants with impaired renal function in 2024. The IQ CPLG Organ Impairment Working Group summarized the industry’s perspective on this guidance by highlighting a few key updates in the 2024 guidance, including: (1) the recommendation of using estimated glomerular filtration rate ...
Yan Jin, Ashish Sharma, Mariam A. Ahmed, Sravanthi Cheeti, Ying Ou, Damayanthi Devineni, Yizhe Chen, Jitendra S. Kanodia, Yasmeen Abouelhassan, Nadia Noormohamed, Jin Zhou, Patrick Marroum, Vaishali Sahasrabudhe, Islam R. Younis   +13 more
wiley   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Role of selenium in the pathophysiology of cardiorenal anaemia syndrome

ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai, Minoru Yasukawa, Shigeru Shibata   +2 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source